|
|
 |
|
Viewing report
|
|
|
|
Mapping the Healthcare Landscape: Bringing Pharmaceuticals into Focus
Datamonitor, Nov 2009, Pages: 116
Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration.
Scope
- Analysis of Big Pharma's current business model, and the mergers, acquisitions and divestments which have shaped it.
- Classification of the human and animal healthcare landscape.
- Analysis of ten healthcare sectors using market size, operating margin, and indicative profit potential.
- Assessment of the healthcare landscape, with key recommendations for pharma companies looking to make future M&A decisions.
Highlights of this title
The average operating margin of pharma-focused companies tends to be higher than that of those with a more diversified business model, implying that increasing pharma-focus is the best strategy to drive profit growth.
Both the market size and operating margin associated with pharmaceuticals makes it the most rewarding of all ten healthcare sectors under analysis, and suggests that diversification on the part of Big Pharma will tend to end in profit dilution.
Patents are key to the high rewards associated with pharmaceuticals, and are also responsible for making the medical device/diagnostics sector the third most attractive sector under analysis, with branding playing a similar role for consumer/over-the-counter health.
Key reasons to purchase this title
- Understand how Big Pharma's business model has evolved, and how this has impacted on operating margin.
- Identify the major sectors within the healthcare landscape, and understand how they relate to one-another.
- Analyze the attractiveness of each sector as a target to diversify into, based on market size, operating profit, and indicative profit potential.
Customers who bought this item also bought
Will Big Pharma Find Success in Generics?
Big Pharma Performance Before, During and Beyond the Global Recession
SPECIAL REPORT: Lessons Learned in the Pharma Industry, 2008
Value-Added Pharma: How to Accomplish the Impossible
Mail Order and Internet Pharmacy in Europe: Embracing the New Challenge
State of the Pharmaceutical Industry 2011 - Industry Remodeling Activities
State of the Pharmaceutical Industry, 2010 - Critical Role of Midsize Pharma
How Big Pharma's R&D Focus Is Changing
Big Pharma’s New Licensing Strategies
Special Report: State of the Pharmaceutical Industry, 2009
|
|
|
|
